SE1250155A1 - Fulvestrant i 500 mg dos för behandling av framskriden bröstcancer - Google Patents
Fulvestrant i 500 mg dos för behandling av framskriden bröstcancer Download PDFInfo
- Publication number
- SE1250155A1 SE1250155A1 SE1250155A SE1250155A SE1250155A1 SE 1250155 A1 SE1250155 A1 SE 1250155A1 SE 1250155 A SE1250155 A SE 1250155A SE 1250155 A SE1250155 A SE 1250155A SE 1250155 A1 SE1250155 A1 SE 1250155A1
- Authority
- SE
- Sweden
- Prior art keywords
- fulvestrant
- patients
- treatment
- dose
- study
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
| PCT/GB2010/051228 WO2011012885A1 (en) | 2009-07-27 | 2010-07-26 | Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE1250155A1 true SE1250155A1 (sv) | 2012-02-22 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1250155A SE1250155A1 (sv) | 2009-07-27 | 2010-07-26 | Fulvestrant i 500 mg dos för behandling av framskriden bröstcancer |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP2017515873A (ja) * | 2014-05-21 | 2017-06-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法 |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| EP3528818B1 (en) * | 2016-10-21 | 2021-09-15 | Crescita Therapeutics Inc. | Pharmaceutical compositions |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 RS RS20120022A patent/RS20120022A1/sr unknown
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Withdrawn
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 FI FI20125207A patent/FI20125207L/fi not_active Application Discontinuation
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en not_active Ceased
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Downton et al. | Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status | |
| Archer et al. | Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women | |
| Rasquin et al. | Polycystic ovarian disease | |
| Payne et al. | A reproductive subtype of depression: conceptualizing models and moving toward etiology | |
| Yonkers et al. | Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder | |
| Mahalingaiah et al. | Targets to treat metabolic syndrome in polycystic ovary syndrome | |
| Yeap et al. | Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials | |
| Croxtall et al. | Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women | |
| Iorfida et al. | Fulvestrant in combination with CDK4/6 inhibitors for HER2-metastatic breast cancers: current perspectives | |
| SE1250155A1 (sv) | Fulvestrant i 500 mg dos för behandling av framskriden bröstcancer | |
| Graham et al. | Clinical predictors of benefit from fulvestrant in advanced breast cancer: a meta-analysis of randomized controlled trials | |
| Koysombat et al. | New advances in menopause symptom management | |
| Joffe et al. | Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. | |
| KR20170005434A (ko) | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 | |
| NO329949B1 (no) | Anvendelse av fulvestrant for fremstilling av medikament ved behandling av resistent brystkreft | |
| Vogel | Primary prevention of breast cancer | |
| AU2023388898A1 (en) | Cancer therapy with capivasertib and fulvestrant | |
| Samsioe et al. | Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study | |
| Zhao et al. | Different cell compositions and a novel somatic KCNJ5 variant found in a patient with bilateral adrenocortical adenomas secreting aldosterone and cortisol | |
| AU2012100098A4 (en) | Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer | |
| Khadoor et al. | The Significance of Serum CA-125 in patients with Polycystic Ovarian Syndrome and its Association with their Hormonal Status | |
| CN101404988A (zh) | 乳腺癌治疗方案 | |
| Marcus et al. | Endometrial Cancer and Precancer in Polycystic Ovary Syndrome | |
| Glynne et al. | Menopausal Hormone Therapy in Primary Care: Benefits and Risks, and How | |
| Glynne et al. | Menopausal Hormone Therapy in Primary Care: Benefits and Risks, and How to Tailor the Dose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAV | Patent application has lapsed |